Literature DB >> 7548798

Interferon therapy for patients more than 60 years of age with chronic hepatitis C.

N Horiike1, T Masumoto, K Nakanishi, K Michitaka, K Kurose, I Ohkura, M Onji.   

Abstract

Nineteen patients aged > 60 years with chronic hepatitis C (CHC) received interferon (IFN) therapy and a complete response (CR) was achieved by five of them (26%). The incidence of CH with severe fibrosis in this elderly group was significantly higher than in another 52 patients with CHC who were < 60 years of age (the younger group; P < 0.05). There was no significant difference in the hepatitis C virus (HCV) genotype distribution between the elderly group and the younger group. However, the HCV-RNA titre was significantly higher in the elderly group than in the younger group (P < 0.05). There was no significant difference in the efficacy rate of IFN in the elderly and younger groups after standardization of the background factors. In the elderly group, the HCV-RNA titre was significantly lower in the patients achieving CR than in those with no response (P < 0.05). These data suggest that elderly patients with a low HCV-RNA titre can still respond well to IFN therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7548798     DOI: 10.1111/j.1440-1746.1995.tb01088.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  10 in total

Review 1.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

2.  Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study.

Authors:  Judith I Tsui; Sue Currie; Hui Shen; Edmund J Bini; Norbert Brau; Teresa L Wright
Journal:  Dig Dis Sci       Date:  2007-09-01       Impact factor: 3.199

Review 3.  Viral hepatitis in elderly haemodialysis patients: current prevention and management strategies.

Authors:  Matthias Girndt
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

4.  Clinical relevance of hepatitis C virus genotypes.

Authors:  P Simmonds
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

Review 5.  Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.

Authors:  Umberto Vespasiani-Gentilucci; Giovanni Galati; Paolo Gallo; Antonio De Vincentis; Elisabetta Riva; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

6.  Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C.

Authors:  C G Nudo; P Wong; N Hilzenrat; M Deschênes
Journal:  Can J Gastroenterol       Date:  2006-09       Impact factor: 3.522

7.  Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score.

Authors:  Hirotoshi Ebinuma; Hidetsugu Saito; Shinichiro Tada; Nobuhiro Nakamoto; Tazuko Ohishi; Satoshi Tsunematsu; Naoki Kumagai; Kanji Tsuchimoto; Nobuhiro Tsukada; Yasutaka Inagaki; Yoshinori Horie; Masahiko Takahashi; Kazuhiro Atsukawa; Yukishige Okamura; Takanori Kanai; Toshifumi Hibi
Journal:  Hepatol Int       Date:  2011-09-10       Impact factor: 6.047

Review 8.  Hepatitis C in the elderly: epidemiology, natural history, and treatment.

Authors:  Ayse L Mindikoglu; Ram R Miller
Journal:  Clin Gastroenterol Hepatol       Date:  2008-12-12       Impact factor: 11.382

Review 9.  Hepatitis C Virus Infection in the Older Patient.

Authors:  Michael Reid; Jennifer C Price; Phyllis C Tien
Journal:  Infect Dis Clin North Am       Date:  2017-12       Impact factor: 5.982

Review 10.  Chronic hepatitis C in the aged: much ado about nothing or nothing to do?

Authors:  Stephen Malnick; Yaakov Maor; Ehud Melzer; Sari Tal
Journal:  Drugs Aging       Date:  2014-05       Impact factor: 3.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.